GLP1R and obesity disorder: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have revolutionized obesity care, thanks to their ability to achieve clinically meaningful WL (15%–20%) after 1–1.5 years of therapy,9 emerging as a cornerstone therapy for the management of obesity and T2D.